Retinal findings raised suspicion for this inherited retinal disease, confirmed with genetic testing.

 New research . . . suggests that a new kind of gene therapy can improve vision in people who have lost nearly all sight to RP.

Significant thickness losses could be detected in outer retinal layers by SD-OCT over a 24-month period in patients with PROM1-associated RD

Patients with XLRP treated with AGTC-501 gene therapy experienced improvements in visual function including retinal sensitivity . . .

Presents a soft artificial retina where flexible ultrathin photosensitive transistors are integrated with three-dimensional stimulation . .

Endogenous regenerative technology involves the use of a patient's biologically active proteins, growth factors and biomaterial scaffolds.

June 17, 2022 | Université de Genève Journal Reference Olivier Mercey, Corinne Kostic, Eloïse Bertiaux, Alexia Giroud, Yashar Sadian,...

UC Berkeley researchers have found that a drug once widely used to wean alcoholics off drinking may help improve sight in mice with RD.

Existing treatments only help a fraction of the estimated 100,000 Americans with this condition. But advances in gene therapy may soon help.

X-linked RP caused by RPGR mutations, an attractive target for gene therapy because of its clinical severity and large number of patients.

Ana B. Garcia-Delgado , Lourdes Valdes-Sanchez , Maria Jose Morillo-Sanchez , Beatriz Ponte-Zuñiga , Francisco J. Diaz-Corrales , Berta...

The FDA has granted orphan drug designation for chemically induced photoreceptor-like cells to treat retinitis pigmentosa.

By: Glenn Yiu, MD, PhD - Department of Ophthalmology & Vision Science, University of California, Davis, Sacramento, California Ophthalmology

FDA granted 4th Orphan Drug Designation for novel gene therapy product candidate (OCU400, Ocugen Inc.) in treatment of PDE6B gene mutation.

Shows promise in stem cell model of retinitis pigmentosa Although the 2017 FDA approval of Spark Therapeutics’ gene therapy Luxturna was...

By Keng Jin Lee and Kanaga Rajan Published JAN 31, 2020

Our goal is to identify the onset of degeneration and devise gene-based therapies to ameliorate or cure the retina disease.

In 1972, Friedman and Roblin proposed that it was theoretically possible to introduce “good” DNA to replace defective DNA.

In 2017, the FDA approved a gene therapy for RP caused by RPE65. The decision marked the first approved treatment for any form RP.

Stem cell-derived cell transplantation in the eye is one therapy being explored for inherited retinal degenerations such as RP.